NEOM partnership aims to accelerate brain-computer interface therapies
Paradromics has received a strategic investment from NEOM, the futuristic Saudi Arabian region, to advance brain-computer interface (BCI) therapies.
Key Highlights:
- NEOM Investment Fund (NIF) will support Paradromics’ Connexus BCI system, designed to help patients communicate after losing speech.
- The partnership includes establishing a BCI Center of Excellence in NEOM to drive clinical research and healthcare innovation.
- Paradromics’ technology deciphers brain signals into health data, initially targeting spinal cord injury, stroke, and ALS patients.
- Future applications include mental health, chronic pain, and speech decoding.
“NEOM and Paradromics share a bold vision for the future of mental health,” said Matt Angle, CEO of Paradromics.
With clinical trials set for 2025, Paradromics is poised to compete with Neuralink, Synchron, and Blackrock Neurotech in the expanding BCI market.
Follow MEDWIRE.AI for updates on neurotechnology innovations.
